Prognostic gene expression signature for high-grade serous ovarian cancer

Background - Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic si...

Full description

Saved in:
Bibliographic Details
Main Authors: Millstein, Joshua (Author) , Turzanski Fortner, Renée (Author) , Sinn, Peter (Author)
Other Authors: Chang-Claude, Jenny (Other) , Herpel, Esther (Other)
Format: Article (Journal)
Language:English
Published: 28 May 2020
In: Annals of oncology
Year: 2020, Volume: 31, Issue: 9, Pages: 1240-1250
ISSN:1569-8041
DOI:10.1016/j.annonc.2020.05.019
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.annonc.2020.05.019
Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0923753420398410
Get full text
Author Notes:J. Millstein, T. Budden, E.L. Goode, M.S. Anglesio, A. Talhouk, M.P. Intermaggio, H.S. Leong, S. Chen, W. Elatre, B. Gilks, T. Nazeran, M. Volchek, R.C. Bentley, C. Wang, D.S. Chiu, S. Kommoss, S.C.Y. Leung, J. Senz, A. Lum, V. Chow, H. Sudderuddin, R. Mackenzie, J. George, AOCS Group, S. Fereday, J. Hendley, N. Traficante, H. Steed, J. M. Koziak, M. Köbel, I.A. McNeish, T. Goranova, D. Ennis, G. Macintyre, D. Silva De Silva, T. Ramón y Cajal, J. García-Donas, S. Hernando Polo, G.C. Rodriguez, K.L. Cushing-Haugen, H.R. Harris, C.S. Greene, R.A. Zelaya, S. Behrens, R.T. Fortner, P. Sinn, E. Herpel, J. Lester, J. Lubiński, O. Oszurek, A. Tołoczko, C. Cybulski, J. Menkiszak, C.L. Pearce, M.C. Pike, C. Tseng, J. Alsop, V. Rhenius, H. Song, M. Jimenez-Linan, A.M. Piskorz, A. Gentry-Maharaj, C. Karpinskyj, M. Widschwendter, N. Singh, C.J. Kennedy, R. Sharma, P.R. Harnett, B. Gao, S.E. Johnatty, R. Sayer, J. Boros, S.J. Winham, G.L. Keeney, S.H. Kaufmann, M.C. Larson, H. Luk, B.Y. Hernandez, P.J. Thompson, L.R. Wilkens, M.E. Carney, B. Trabert, J. Lissowska, L. Brinton, M.E. Sherman, C. Bodelon, S. Hinsley, L.A. Lewsley, R. Glasspool, S. N. Banerjee, E. A. Stronach, P. Haluska, I. Ray-Coquard, S. Mahner, B. Winterhoff, D. Slamon, D. A. Levine, L. E. Kelemen, J. Benitez, J. Chang-Claude, J. Gronwald, A.H. Wu, U. Menon, M.T. Goodman, J.M. Schildkraut, N. Wentzensen, R. Brown, A. Berchuck, G. Chenevix-Trench, A. deFazio, S.A. Gayther, M.J. García, M.J. Henderson, M.A. Rossing, A. Beeghly-Fadiel, P A. Fasching, S. Orsulic, B.Y. Karlan, G.E. Konecny, D.G. Huntsman, D.D. Bowtell, J.D. Brenton, J.A. Doherty, P.D.P. Pharoah & S.J. Ramus
Description
Summary:Background - Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic signature for OS in patients with HGSOC. - Patients and methods - Expression of 513 genes, selected from a meta-analysis of 1455 tumours and other candidates, was measured using NanoString technology from formalin-fixed paraffin-embedded tumour tissue collected from 3769 women with HGSOC from multiple studies. Elastic net regularization for survival analysis was applied to develop a prognostic model for 5-year OS, trained on 2702 tumours from 15 studies and evaluated on an independent set of 1067 tumours from six studies. - Results - Expression levels of 276 genes were associated with OS (false discovery rate < 0.05) in covariate-adjusted single-gene analyses. The top five genes were TAP1, ZFHX4, CXCL9, FBN1 and PTGER3 (P < 0.001). The best performing prognostic signature included 101 genes enriched in pathways with treatment implications. Each gain of one standard deviation in the gene expression score conferred a greater than twofold increase in risk of death [hazard ratio (HR) 2.35, 95% confidence interval (CI) 2.02-2.71; P < 0.001]. Median survival [HR (95% CI)] by gene expression score quintile was 9.5 (8.3 to -), 5.4 (4.6-7.0), 3.8 (3.3-4.6), 3.2 (2.9-3.7) and 2.3 (2.1-2.6) years. - Conclusion - The OTTA-SPOT (Ovarian Tumor Tissue Analysis consortium - Stratified Prognosis of Ovarian Tumours) gene expression signature may improve risk stratification in clinical trials by identifying patients who are least likely to achieve 5-year survival. The identified novel genes associated with the outcome may also yield opportunities for the development of targeted therapeutic approaches.
Item Description:AOCS Study Group: D. Bowtell, G. Chenevix-Trench, A. Green, P. Webb, A. DeFazio, D. Gertig, N. Traficante, S. Fereday, S. Moore, J. Hung, K. Harrap, T. Sadkowsky, N. Pandeya, M. Malt, A. Mellon, R. Robertson, T. Vanden Bergh, M. Jones, P. Mackenzie, J. Maidens, K. Nattress, Y.E. Chiew, A. Stenlake, H. Sullivan, B. Alexander, P. Ashover, S. Brown, T. Corrish, L. Green, L. Jackman, K. Ferguson, K. Martin, A. Martyn, B. Ranieri, J. White, V. Jayde, P. Mamers, L. Bowes, L. Galletta, D. Giles, J. Hendley, K. Alsop, T. Schmidt, H. Shirley, C. Ball, C. Young, S. Viduka, Hoa Tran, Sanela Bilic, Lydia Glavinas, Julia Brooks, R. Stuart-Harris, F. Kirsten, J. Rutovitz, P. Clingan, A. Glasgow, A. Proietto, S. Braye, G. Otton, J. Shannon, T. Bonaventura, J. Stewart, S. Begbie, M. Friedlander, D. Bell, S. Baron-Hay, A. Ferrier, G. Gard, D. Nevell, N. Pavlakis, S. Valmadre, B. Young, C. Camaris, R. Crouch, L. Edwards, N. Hacker, D. Marsden, G. Robertson, P. Beale, J. Beith, J. Carter, C. Dalrymple, R. Houghton, P. Russell, M. Links, J. Grygiel, J. Hill, A. Brand, K. Byth, R. Jaworski, P. Harnett, R. Sharma, G. Wain, B. Ward, D. Papadimos, A. Crandon, M. Cummings, K. Horwood, A. Obermair, L. Perrin, D. Wyld, J. Nicklin, M. Davy, M.K. Oehler, C. Hall, T. Dodd, T. Healy, K. Pittman, D. Henderson, J. Miller, J. Pierdes, P. Blomfield, D. Challis, R. McIntosh, A. Parker, B. Brown, R. Rome, D. Allen, P. Grant, S. Hyde, R. Laurie, M. Robbie, D. Healy, T. Jobling, T. Manolitsas, J. McNealage, P. Rogers, B. Susil, E. Sumithran, I. Simpson, K. Phillips, D. Rischin, S. Fox, D. Johnson, S. Lade, M. Loughrey, N. O’Callaghan, W. Murray, P. Waring, V. Billson, J. Pyman, D. Neesham, M. Quinn, C. Underhill, R. Bell, L.F. Ng, R. Blum, V. Ganju, I. Hammond, Y. Leung, A. McCartney, M. Buck, I. Haviv, D. Purdie, D. Whiteman, N. Zeps
Gesehen am 29.09.2020
Physical Description:Online Resource
ISSN:1569-8041
DOI:10.1016/j.annonc.2020.05.019